CJC+Ipamorelin 10 & 20mg

Chemical Name/Structure

Because this product is a synergistic combination of two distinct growth hormone secretagogues, its chemical details are defined by its individual active constituents:

• CJC-1295 Acetate (Without DAC / Modified GRF 1-29)

  • Chemical Name: L-tyrosyl-D-alanyl-L-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-glutaminyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-L-alanyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-aspartyl-L-isoleucyl-L-leucyl-L-seryl-L-argininamide acetate

  • Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2

• Ipamorelin Acetate

  • Chemical Name: 2-methylalanyl-L-histidyl-3-(2-naphthalenyl)-D-alanyl-D-phenylalanyl-L-lysinamide acetate

  • Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2

CAS Number

• CJC-1295 (Modified GRF 1-29): 863288-34-0 (or 446262-90-4)

• Ipamorelin: 170851-70-4

Core Areas of Research Investigation

• Synergistic Growth Hormone (GH) Release: Investigating how the dual activation of the Growth Hormone-Releasing Hormone (GHRH) receptor (via CJC-1295) and the Ghrelin/Growth Hormone Secretagogue receptor (via Ipamorelin) produces a amplified, pulsatile GH release.

• Adipose Tissue Metablism & Lipolysis: Evaluating the combined impact of elevated growth hormone cascades on lipid oxidation, free fatty acid mobilization, and the reduction of deep visceral adipose tissue (VAT).

• Musculoskeletal Regeneration & IGF-1 Expression: Studying how continuous, pulsatile growth hormone secretion promotes hepatic IGF-1 synthesis to stimulate muscle cell proliferation, nitrogen retention, and connective tissue repair.

• Selective Pituitary Somatotroph Stimulation: Analyzing the safety and regulatory patterns of the pituitary gland when stimulated without elevating secondary stress hormones like cortisol, ACTH, or prolactin.

• Bone Density & Mineralization Pathways: Probing the potential of dual secretagogue administration to enhance osteoblast activity and counteract age-related or glucocorticoid-induced bone mineral decline.

RESEARCH-USE NOTICE

This product is supplied by Biolabs for laboratory and research purposes only. It is not intended to diagnose, treat, cure, or prevent any medical condition and should not be used as a substitute for professional medical advice or treatment.

Any information provided is for general research, product identification, storage, and handling purposes only. The purchaser is responsible for using and storing the product appropriately and in accordance with applicable regulations.

.